secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001193125-24-255110
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics Q3 revenue up 4% to $18.5M; net loss widens to $13.3M; stockholders approve Greenbrook deal
--------------------------------------------------------------------------------

- Revenue $18.5M (+4% YoY); U.S. system revenue $4.1M (+14%) on 48 units; treatment session revenue $13.3M (+2%)
- Gross margin improved to 75.6% from 65.8% due to product mix and absence of prior-year manufacturing costs
- Net loss widened to $13.3M ($0.44/sh) from $9.4M ($0.33/sh) in Q3 2023; EBITDA -$11.6M vs -$7.7M; cash $20.9M
- Stockholders approved Greenbrook acquisition Nov 8; court hearing Nov 15; expect cash flow breakeven by Q2 2025
- Full-year 2024 revenue guidance narrowed to $71-72M; Q4 2024 revenue guidance $19-20M

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524255110/0001193125-24-255110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000119312524255110/d910083d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-255110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer